Management of Antithrombotic Therapy after Acute Coronary Syndromes.
作者信息
Rodriguez Fatima, Harrington Robert A
机构信息
From the Division of Cardiovascular Medicine, Department of Medicine, and the Stanford Cardiovascular Institute (F.R., R.A.H.), Stanford University, Palo Alto, CA.
出版信息
N Engl J Med. 2021 Feb 4;384(5):452-460. doi: 10.1056/NEJMra1607714.
Abstract
摘要
相似文献
1
Management of Antithrombotic Therapy after Acute Coronary Syndromes.急性冠状动脉综合征后抗栓治疗的管理
N Engl J Med. 2021 Feb 4;384(5):452-460. doi: 10.1056/NEJMra1607714.
2
Antithrombotic Therapy after Acute Coronary Syndromes. Reply.急性冠状动脉综合征后的抗栓治疗。回复。
N Engl J Med. 2021 May 13;384(19):1873-1874. doi: 10.1056/NEJMc2103789.
3
[Antithrombotic treatment in acute coronary syndrome].[急性冠状动脉综合征的抗栓治疗]
Dtsch Med Wochenschr. 2014 Jan;139 Suppl 1:S17-22. doi: 10.1055/s-0033-1359997. Epub 2014 Jan 20.
4
Antithrombotic treatment in acute coronary syndromes.急性冠脉综合征的抗血栓治疗。
Minerva Med. 2010 Aug;101(4):215-38.
5
Challenges in managing venous thromboembolism and acute coronary syndrome: case studies of the use of antithrombotic and antiplatelet therapies. Introduction.静脉血栓栓塞症和急性冠状动脉综合征管理中的挑战：抗血栓和抗血小板治疗应用的案例研究。引言。
Am J Health Syst Pharm. 2008 Aug 1;65(15 Suppl 7):S3-4. doi: 10.2146/ajhp080239.
6
Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes.非ST段抬高型急性冠状动脉综合征内科治疗患者的抗栓治疗
Heart. 2016 Jun 1;102(11):882-92. doi: 10.1136/heartjnl-2014-306695. Epub 2016 Mar 4.
7
[Path of exploration for the optimal antithrombotic treatment strategy for patients with coronary heart disease].[冠心病患者最佳抗栓治疗策略的探索路径]
Zhonghua Xin Xue Guan Bing Za Zhi. 2022 May 24;50(5):429-431. doi: 10.3760/cma.j.cn112148-20220324-00206.
8
Comparative Effects of Genetic and Nongenetic Factors in Antithrombotic Strategy.抗栓策略中遗传因素与非遗传因素的比较效应
J Atheroscler Thromb. 2023 Dec 1;30(12):1763-1765. doi: 10.5551/jat.ED242. Epub 2023 Sep 20.
9
Antithrombotic drugs.抗血栓药物。
Treat Guidel Med Lett. 2011 Oct;9(110):61-6; quiz 2 p following 66.
10
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation - Dual versus triple antithrombotic therapy.无持续性ST段抬高且合并心房颤动患者的急性冠状动脉综合征管理——双联与三联抗栓治疗
Eur Heart J. 2021 May 21;42(20):2020-2021. doi: 10.1093/eurheartj/ehaa909.
引用本文的文献
1
Comparative Safety of Anticoagulant, Antiplatelet and the Combination of Both for Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.抗凝剂、抗血小板药物及其联合应用治疗急性冠脉综合征的比较安全性：一项系统评价和网状Meta分析
Biomedicines. 2025 Aug 20;13(8):2027. doi: 10.3390/biomedicines13082027.
2
Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease: A Secondary Analysis of a Randomized Clinical Trial.从替格瑞洛降阶梯至氯吡格雷用于慢性肾脏病合并心肌梗死：一项随机临床试验的二次分析
JAMA Netw Open. 2025 May 1;8(5):e2511297. doi: 10.1001/jamanetworkopen.2025.11297.
3
Development of a multidimensional prediction model for long-term prognostic risk in patients with acute coronary syndromes after percutaneous coronary intervention: A retrospective observational cohort study.经皮冠状动脉介入治疗后急性冠状动脉综合征患者长期预后风险的多维预测模型的开发：一项回顾性观察队列研究。
PLoS One. 2025 May 7;20(5):e0318445. doi: 10.1371/journal.pone.0318445. eCollection 2025.
4
Ticagrelor versus Clopidogrel After Left Main Coronary Artery Disease Intervention.左主干冠状动脉疾病介入治疗后替格瑞洛与氯吡格雷的比较
Cardiovasc Drugs Ther. 2025 May 1. doi: 10.1007/s10557-025-07709-x.
5
Intersections and Challenges in the Management of Acute Coronary Syndrome and Stroke: Pathophysiology, Treatment Dilemmas, and Integrated Prevention Strategies.急性冠状动脉综合征与中风管理中的交叉点和挑战：病理生理学、治疗困境及综合预防策略
J Clin Med. 2025 Mar 29;14(7):2354. doi: 10.3390/jcm14072354.
6
Characterization and anticoagulation treatment patterns of hospitalized patients with nonvalvular atrial fibrillation in Spain: The CARISMA registry.西班牙非瓣膜性心房颤动住院患者的特征及抗凝治疗模式：CARISMA注册研究
Int J Cardiol Heart Vasc. 2025 Mar 1;57:101639. doi: 10.1016/j.ijcha.2025.101639. eCollection 2025 Apr.
7
ANti-Thrombotic strAtegy for the management of nonocclusive thRombus with ST-segment elevation myocardial infarCtion in young pAtients - ANTARTICA study.年轻患者ST段抬高型心肌梗死非闭塞性血栓管理的抗栓策略——南极洲研究
Indian Heart J. 2025 Jan-Feb;77(1):14-21. doi: 10.1016/j.ihj.2024.12.003. Epub 2024 Dec 20.
8
Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial.复杂高危 PCI 患者抗血小板治疗的时间调制（早期强化和晚期下调）：TAILORED-CHIP 试验的原理和设计。
EuroIntervention. 2024 Nov 4;20(21):e1355-e1362. doi: 10.4244/EIJ-D-24-00437.
9
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial.替格瑞洛联合或不联合阿司匹林对经皮冠状动脉介入治疗后总出血及再发出血和缺血事件的影响：TWILIGHT试验的一项子研究
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):66-74. doi: 10.1093/ehjcvp/pvae080.
10
Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.急性冠状动脉综合征患者药物洗脱支架置入术后的短期双联抗血小板治疗：一项系统评价和网状Meta分析
JAMA Cardiol. 2024 Dec 1;9(12):1094-1105. doi: 10.1001/jamacardio.2024.3216.
本文引用的文献
1
The 'Ten Commandments' for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.2020年欧洲心脏病学会（ESC）非持续性ST段抬高型急性冠状动脉综合征患者管理指南的“十诫”
Eur Heart J. 2020 Oct 1;41(37):3495-3497. doi: 10.1093/eurheartj/ehaa624.
2
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.阿司匹林停药联合经皮冠状动脉介入治疗后患者 P2Y 抑制剂的安全性和有效性：系统评价和荟萃分析。
Circulation. 2020 Aug 11;142(6):538-545. doi: 10.1161/CIRCULATIONAHA.120.046251. Epub 2020 Jun 19.
3
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.替格瑞洛单药治疗与替格瑞洛联合阿司匹林治疗对急性冠状动脉综合征患者主要出血和心血管事件的影响：TICO 随机临床试验。
JAMA. 2020 Jun 16;323(23):2407-2416. doi: 10.1001/jama.2020.7580.
4
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.急性冠状动脉综合征或经皮冠状动脉介入治疗后早期和晚期心房颤动患者抗栓治疗的风险/获益权衡：来自 AUGUSTUS 的见解。
Circulation. 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29.
5
Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review.当代急性冠状动脉综合征临床试验中老年患者、女性和种族/少数民族群体的入组情况：一项系统评价。
JAMA Cardiol. 2020 Jun 1;5(6):714-722. doi: 10.1001/jamacardio.2020.0359.
6
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.阿司匹林剂量 - 以患者为中心的试验评估获益和长期有效性（ADAPTABLE）试验的原理和设计。
JAMA Cardiol. 2020 May 1;5(5):598-607. doi: 10.1001/jamacardio.2020.0116.
7
Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.经皮冠状动脉介入治疗后心房颤动的双联与三联治疗：系统评价和荟萃分析。
Ann Intern Med. 2020 Apr 7;172(7):474-483. doi: 10.7326/M19-3763. Epub 2020 Mar 17.
8
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.《心脏病与卒中统计-2020 更新：来自美国心脏协会的报告》。
Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29.
9
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.长期使用替格瑞洛对既往有心肌梗死且无冠状动脉支架置入史患者进行二级预防：来自PEGASUS-TIMI 54研究的见解
Eur Heart J. 2020 May 1;41(17):1625-1632. doi: 10.1093/eurheartj/ehz821.
10
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.替格瑞洛联合阿司匹林在急性冠状动脉综合征中的获益与风险：随机 GLOBAL LEADERS 试验的事后分析。
JAMA Cardiol. 2019 Nov 1;4(11):1092-1101. doi: 10.1001/jamacardio.2019.3355.
Zotero 插件